During the past two decades, induced pluripotent stem cells (iPSCs) have been widely used
to study mechanisms of human neural development, disease modeling, and drug discovery …

Blood-brain barrier disruption occurs in the early stages of Alzheimer's disease. Recent
studies indicate a link between blood-brain barrier dysfunction and cognitive decline and …

There is ample pathological and biological evidence for endo-lysosomal dysfunction in
Alzheimer's disease (AD) and emerging genetic studies repeatedly implicate endo …

Parkinson's disease (PD) as a progressive neurodegenerative disorder arises from multiple
genetic and environmental factors. However, underlying pathological mechanisms remain …

Understanding the pathophysiology of CNS-associated neurological diseases has been
hampered by the inaccessibility of patient brain tissue to perform live analyses at the …

Iron metabolism disorders are implicated in the pathogenesis of Alzheimer's disease (AD). It
was previously reported that transferrin receptor (TFR1) expression was upregulated in AD …

A reoccurring issue in neuroepigenomic studies, especially in the context of
neurodegenerative disease, is the use of (heterogeneous) bulk tissue, which generates …

Parkinson's disease (PD) as a progressive neurodegenerative disorder arises from multiple
genetic and environmental factors. However, underlying pathological mechanisms remain …

The establishment of human‐induced pluripotent stem cell (iPSC) models from sporadic
Alzheimer's disease (sAD) patients is necessary and could potentially benefit research into …

Blood-brain barrier disruption occurs in the early stages of Alzheimer's disease. Recent
studies indicate a link between blood-brain barrier dysfunction and cognitive decline and …